Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DRUG DIVERSION BILL EMERGENCY SCHEDULING EXEMPTION

Executive Summary

DRUG DIVERSION BILL EMERGENCY SCHEDULING EXEMPTION should be specifically granted to investigational drugs, PMA urged in recent comments submitted to House Health Subcmte. Chairman Waxman (D-Calif.). Commenting on the proposed provision giving the Justice Dept.'s Drug Enforcement Administration emergency drug scheduling authority, PMA said that an amendment should be added to "explicitly prohibit the emergency scheduling of pharmaceutical products having accepted medical use in the U.S. or which are being investigated to establish that use." The bill was introduced by House Judiciary Courts Subcmte. Chairman Hughes (D-NJ). Although the bill was amended by the House Judiciary's Courts Subcmte. in April to limit emergency scheduling authority to only those substances with "no currently acceptable medical use," PMA contended that the provision could be interpreted to allow emergency scheduling of investigational drugs. The assn. asserted that the bill "could permit the attorney general to temporarily schedule a compound which is the subject of an investigational new drug exemption (IND) because, technically, many IND drugs have no currently accepted medical value since they have not yet been approved by FDA for marketing." PMA submitted the comments following a July 31 hearing by the House Health & Environment Subcmte.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel